Press Release
<< Back
Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic
Details of the symposium and poster presentation are as follows:
Abstract Title: Trials in progress: A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcoma
Where: The
When:
Symposium Website: Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic
“The Epigenetics Symposium is an ideal event to showcase our progress bringing our lead drug candidate, Seclidemstat, into the clinic and the impact it could have on Ewing sarcoma, a rare and deadly bone cancer that most often strikes children and young adults and for which there are no targeted therapies approved,” stated
About
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as “will,” “can,” “could,” “believe,” “plan,” “allow,” “expect,” “provide,” “able to,” “position,” “anticipate,” “progress,” “potential,” and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements regarding: the progress in bringing Seclidemstat into the clinic and the impact it could have on Ewing sarcoma; the development of Seclidemstat to be a differentiated LSD1 inhibitor; the potential of Seclidemstat; anticipated timing of release of early cohort data from the company’s Ewing sarcoma study and a Phase 1 study in advanced solid tumors; the company’s belief that Seclidemstat is one of only two reversible inhibitors of LSD1 currently in human trials and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies; and the company’s development of Seclidemstat for several cancers with high unmet medical need, including prostate, breast and ovarian cancers. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of the company to raise additional capital to meet the company’s business operational needs and to achieve its business objectives and strategy; the company’s ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius’ intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius to access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius’ cash resources; and other risks described in Salarius’ filings with the
Contacts
Investor Relations
Managing Director
(212) 915-2568
jeremy@lifesciadvisors.com
Media Relations:
Senior Vice President
(212) 375-2686
jbennett@tiberend.com
Source: Salarius Pharmaceuticals